李 颖,曹海霞

肺炎支原体肺炎（MPP）主要由肺炎支原体引起，是一种常见的儿童呼吸系统疾病，约占儿童社区获得性肺炎病例的10-40%。虽然MPP通常是一种良性和自限性疾病，但仍有约10%的MPP患儿经大环内酯类抗生素规范治疗后会进展为难治性肺炎支原体肺炎（RMPP），RMPP是指大环内酯类药物治疗7天及以上，临床征象加重、仍持续发热，肺部影像学表现加重的MPP，具有病情进展快，病程迁延等特点，严重危及患儿生命健康。近年来RMPP发病率逐年升高，早期不易识别，治疗难度大，甚至危及生命，给患儿及家庭造成严重的后果。因此，及早识别RMPP并及时治疗以防止疾病进展对儿科医生至关重要。

难治性肺炎支原体肺炎；早期预测；儿童

[1] Fangfang S,Chunjuan D,Tongqiang Z,et al.Development of a Nomogram for Predicting Refractory Mycoplasma pneumoniae Pneumonia in Children[J].Frontiers in Pediatrics,2022,10813614-813614. [2] Hui G,Baijun S,Ye C,et al.The risk factors of children acquiring refractory mycoplasma pneumoniae pneumonia:A meta-analysis[J]. Medicine,2021,100(11):e24894-e24894. [3] 曲百娜,迟磊,朱紫微,等.儿童难治性肺炎支原体肺炎的临床特征及高危因素分析[J].中国中西医结合儿科学,2019,11(02):144-148. [4] Lee K L,Lee C M,Yang T L,et al.Severe Mycoplasma pneumoniae pneumonia requiring intensive care in children,2010–2019[J]. Journal of the Formosan Medical Association,2021,120(1):281-291. [5] Naoyuki O,Motoshi O,Kazuharu M,et al.Hypouricemia and Urate Transporters[J].Biomedicines,2022,10(3):652-652. [6] Simone A,Mercedes G,Rossana P,et al.The Good,the Bad and the New about Uric Acid in Cancer[J].Cancers,2022,14(19):4959-4959. [7] Shen W,Sun X.Construction of a nomogram for early diagnosis of refractory Mycoplasma pneumoniae pneumonia in children[J]. Translational Pediatrics,2024,13(7):1119. [8] Keller K,Beule J,Balzer O J,et al.D-Dimer and thrombus burden in acute pulmonary embolism[J].American Journal of Emergency Medicine,2018,36(9):1613-1618. [9] Jin X,Zhu Y,Zhang Y,et al.Assessment of levels of D_x001e_dimer and interferon_x001e_γin pediatric patients with Mycoplasma pneumoniae pneumonia and its clinical implication[J].Experimental and therapeutic medicine,2018,16(6):5025-5030. [10] Huang X,Li D,Liu F,et al.Clinical significance of D-dimer levels in refractory Mycoplasma pneumoniae pneumonia[J].BMC infectious diseases,2021,21:1-8. [11] Chen Q,Hu T,Wu L,et al.Clinical Features and Biomarkers for Early Prediction of Refractory Mycoplasma Pneumoniae Pneumonia in Children.[J].Emergency medicine international,2024,20249328177-9328177. [12] Xue D,Zheng Y,Wen J,et al.Role of chemokines in hepatocellular carcinoma[J].Oncology Reports,2021,45(3):809-823. [13] Hughes C E,Nibbs R J B.A guide to chemokines and their receptors[J].The FEBS journal,2018,285(16):2944-2971. [14] He Y S,Yang M,Qian S Y.Predictive role of cytokines in children with refractory mycoplasma pneumoniae pneumonia[J].Zhonghua er ke za zhi=Chinese journal of pediatrics,2021,59(5):422-425. [15] Hue E,Orard M,Toquet M P,et al.Asymmetrical pulmonary cytokine profiles are linked to bronchoalveolar lavage fluid cytology of horses with mild airway neutrophilia[J].Frontiers in Veterinary Science,2020,7:226. [16] Lee Y C,Chang C H,Lee W J,et al.Altered chemokine profile in Refractory Mycoplasma pneumoniae pneumonia infected children[J]. Journal of Microbiology,Immunology and Infection,2021,54(4):673-679. [17] Latchman Y,Wood C R,Chernova T,et al.PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J].Nature immunology,2001, 2(3):261-268. [18] Tseng S Y,Otsuji M,Gorski K,et al.B7-DC,a new dendritic cell molecule with potent costimulatory properties for T cells[J].The Journal of experimental medicine,2001,193(7):839-846. [19] Groeger S,Howaldt H P,Raifer H,et al.Oral squamous carcinoma cells express B7-H1 and B7-DC receptors in vivo[J].Pathology& Oncology Research,2017,23:99-110. [20] Matsumoto K,Fukuyama S,Eguchi-Tsuda M,et al.B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma[J].Biochemical and biophysical research communications,2008,365(1):170-175. [21] WenHua Z,MinPing Z,YuYun Z,et al.The predictive values of soluble B7-DC in children with refractory mycoplasma pneumoniae pneumonia.[J].Translational pediatrics,2023,12(3):396-404. [22] Ntatsoulis K,Karampitsakos T,Tsitoura E,et al.Commonalities between ARDS,pulmonary fibrosis and COVID-19:the potential of autotaxin as a therapeutic target[J].Frontiers in Immunology,2021,12:687397.Andersson U,Tracey K J.HMGB1 is a therapeutic target for sterile inflammation and infection[J].Annual review of immunology,2011,29(1):139-162. [23] 王星,刘辉,庞辉,等.血清SAA､YKL-40及SP-A的联合检测对小儿难治性肺炎支原体肺炎的预测价值分析[J].现代生物医学进展,2023,23(07):1309-1314. [24] Andersson U,Tracey K J.HMGB1 is a therapeutic target for sterile inflammation and infection[J].Annual review of immunology, 2011,29(1):139-162. [25] Ying D,Chu C,Yuqin L,et al.High expression of HMGB1 in children with refractory Mycoplasma pneumoniae pneumonia.[J].BMC infectious diseases,2018,18(1):439. [26] Tian G,Jianwei Y,Jun H.miRNA,lncRNA and circRNA:targeted molecules with therapeutic promises in Mycoplasma pneumoniae infection.[J].Archives of microbiology,2023,205(8):293-293. [27] S L K,S M A,W V L S,et al.The biogenesis,biology and characterization of circular RNAs.[J].Nature reviews.Genetics,2019,20(11):675-691. [28] Lou Z,Zhou R,Su Y,et al.Minor and major circRNAs in virus and host genomes[J].Journal of Microbiology,2021,59:324-331. [29] 穆世茵,邹映雪,郭永盛,等.儿童难治性肺炎支原体肺炎的危险因素及其预测效能[J].山东医药,2024,64(23):11-15. [30] Gong H,Sun B,Chen Y,et al.The risk factors of children acquiring refractory mycoplasma pneumoniae pneumonia:a meta-analysis[J]. Medicine,2021,100(11):e24894. [31] 鲁靖,赵顺英,宋蕾,等.不同影像学表现的儿童肺炎支原体肺炎临床特征[J].中华实用儿科临床杂志,2017,32(4):284-288. [32] 陈锋,张芙蓉.儿童难治性肺炎支原体肺炎的早期临床特点及相关危险因素[J].China Tropical Medicine,2024,24(7).

点击下载PDF